BACKGROUND & AIMS: Hepatitis C virus (HCV) establishes chronic infections in 3% of the world's population. Infection leads to progressive liver disease; hepatocytes are the major site of viral replication in vivo. However, chronic infection is associated with a variety of extrahepatic syndromes, including central nervous system (CNS) abnormalities. We therefore screened a series of neural and brain-derived cell lines for their ability to support HCV entry and replication. METHODS: We used a panel of neural-derived cell lines, HCV pseudoparticles (HCVpp), and an infectious, HCV JFH-1 cell-culture system (HCVcc) to assess viral tropism. RESULTS: Two independently derived neuroepithelioma cell lines (SK-N-MC and SK-PN-DW) permitted HCVpp entry. In contrast, several neuroblastoma, glioma, and astrocytoma cell lines were refractory to HCVpp infection. HCVcc infected the neuroepithelioma cell lines and established a productive infection. Permissive neuroepithelioma cells expressed CD81, scavenger receptor BI (SR-BI), and the tight junction proteins Claudin-1 (CLDN1) and occludin, whereas nonpermissive neural cell lines lacked CLDN1 and, in some cases, SR-BI. HCVpp infection of the neuroepithelioma cells was neutralized by antibodies to CD81, SR-BI, CLDN1, and HCV E2. Furthermore, anti-CD81, interferon, and the anti-NS3 protease inhibitor VX-950 significantly reduced HCVcc infection of neuroepithelioma and hepatoma cells. CONCLUSIONS: Neuroepithelioma-derived cell lines express functional receptors that support HCV entry at levels comparable to those of hepatoma cells. HCV infection in vitro is not restricted to hepatic-derived cells, so HCV might infect cells of the CNS in vivo.
BACKGROUND & AIMS: Hepatitis C virus (HCV) establishes chronic infections in 3% of the world's population. Infection leads to progressive liver disease; hepatocytes are the major site of viral replication in vivo. However, chronic infection is associated with a variety of extrahepatic syndromes, including central nervous system (CNS) abnormalities. We therefore screened a series of neural and brain-derived cell lines for their ability to support HCV entry and replication. METHODS: We used a panel of neural-derived cell lines, HCV pseudoparticles (HCVpp), and an infectious, HCV JFH-1 cell-culture system (HCVcc) to assess viral tropism. RESULTS: Two independently derived neuroepithelioma cell lines (SK-N-MC and SK-PN-DW) permitted HCVpp entry. In contrast, several neuroblastoma, glioma, and astrocytoma cell lines were refractory to HCVpp infection. HCVcc infected the neuroepithelioma cell lines and established a productive infection. Permissive neuroepithelioma cells expressed CD81, scavenger receptor BI (SR-BI), and the tight junction proteins Claudin-1 (CLDN1) and occludin, whereas nonpermissive neural cell lines lacked CLDN1 and, in some cases, SR-BI. HCVpp infection of the neuroepithelioma cells was neutralized by antibodies to CD81, SR-BI, CLDN1, and HCV E2. Furthermore, anti-CD81, interferon, and the anti-NS3 protease inhibitor VX-950 significantly reduced HCVcc infection of neuroepithelioma and hepatoma cells. CONCLUSIONS: Neuroepithelioma-derived cell lines express functional receptors that support HCV entry at levels comparable to those of hepatoma cells. HCV infection in vitro is not restricted to hepatic-derived cells, so HCV might infect cells of the CNS in vivo.
Authors: Sara Casado-Zapico; Jezabel Rodriguez-Blanco; Guillermo García-Santos; Vanesa Martín; Ana M Sánchez-Sánchez; Isaac Antolín; Carmen Rodriguez Journal: J Pineal Res Date: 2010-01 Impact factor: 13.007
Authors: Jennifer M Timpe; Zania Stamataki; Adam Jennings; Ke Hu; Michelle J Farquhar; Helen J Harris; Anne Schwarz; Isabelle Desombere; Geert Leroux Roels; Peter Balfe; Jane A McKeating Journal: Hepatology Date: 2008-01 Impact factor: 17.425
Authors: Brett D Lindenbach; Matthew J Evans; Andrew J Syder; Benno Wölk; Timothy L Tellinghuisen; Christopher C Liu; Toshiaki Maruyama; Richard O Hynes; Dennis R Burton; Jane A McKeating; Charles M Rice Journal: Science Date: 2005-06-09 Impact factor: 47.728
Authors: Joe Grove; Søren Nielsen; Jin Zhong; Margaret F Bassendine; Heidi E Drummer; Peter Balfe; Jane A McKeating Journal: J Virol Date: 2008-10-01 Impact factor: 5.103
Authors: Qiang Ding; Markus von Schaewen; Gabriela Hrebikova; Brigitte Heller; Lisa Sandmann; Mario Plaas; Alexander Ploss Journal: J Virol Date: 2017-01-31 Impact factor: 5.103
Authors: David A Sheridan; S H Bridge; M M E Crossey; D J Felmlee; H C Thomas; R D G Neely; S D Taylor-Robinson; M F Bassendine Journal: Metab Brain Dis Date: 2014-03-12 Impact factor: 3.584
Authors: Daniel Da Costa; Marine Turek; Daniel J Felmlee; Erika Girardi; Sébastien Pfeffer; Gang Long; Ralf Bartenschlager; Mirjam B Zeisel; Thomas F Baumert Journal: J Virol Date: 2012-08-15 Impact factor: 5.103
Authors: Kenneth L Hastings; Martin D Green; Bin Gao; Patricia E Ganey; Robert A Roth; Gary R Burleson Journal: Int J Toxicol Date: 2020 Mar/Apr Impact factor: 2.032